HC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target to $10.00

Invivyd (NASDAQ:IVVD) had its target price cut by HC Wainwright from $15.00 to $10.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.63) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.

Separately, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.70 on Wednesday. Invivyd has a 1 year low of $0.69 and a 1 year high of $5.20. The firm has a 50-day moving average of $0.97 and a 200 day moving average of $1.24. The stock has a market cap of $83.90 million, a P/E ratio of -0.36 and a beta of 0.65.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC purchased a new position in shares of Invivyd in the third quarter worth $27,000. XTX Topco Ltd raised its position in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after buying an additional 15,376 shares during the last quarter. SG Americas Securities LLC lifted its stake in Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after acquiring an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. purchased a new stake in shares of Invivyd during the 2nd quarter valued at about $86,000. Finally, Rhumbline Advisers grew its stake in shares of Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares during the period. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.